Hepatitis Monthly

Published by: Kowsar

Egy-Score Predicts Severe Hepatic Fibrosis and Cirrhosis in Egyptians With Chronic Liver Diseases: A Pilot Study

Mohamed A. Alboraie 1 , * , Mahmoud E. Afifi 1 , Fathy G. Elghamry 1 , Helmy A. Shalaby 1 , Gamal E. Elshennawy 1 , Ahmed A. Abdelaziz 1 , Mohamed U. Shaheen 2 and Amany R. Abo El-Seoud 3
Authors Information
1 Department of Internal Medicine, Al-Azhar University, Cairo, Egypt
2 Department of Clinical Pathology, Al-Azhar University, Cairo, Egypt
3 Department of Community Medicine and Public Health, Zagazig University, Zagazig, Egypt
Article information
  • Hepatitis Monthly: June 01, 2013, 13 (6); e10810
  • Published Online: June 16, 2013
  • Article Type: Research Article
  • Received: February 18, 2013
  • Revised: April 2, 2013
  • Accepted: April 20, 2013
  • DOI: 10.5812/hepatmon.10810

To Cite: Alboraie M A, Afifi M E, Elghamry F G, Shalaby H A, Elshennawy G E, et al. Egy-Score Predicts Severe Hepatic Fibrosis and Cirrhosis in Egyptians With Chronic Liver Diseases: A Pilot Study, Hepat Mon. 2013 ; 13(6):e10810. doi: 10.5812/hepatmon.10810.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lai M, Afdhal NH. Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade. Am J Gastroenterol. 2011; 106(12): 2121-2[DOI][PubMed]
  • 2. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008; 134(6): 1670-81[DOI][PubMed]
  • 3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[DOI][PubMed]
  • 4. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371(9615): 838-51[DOI][PubMed]
  • 5. Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol. 2012; 18(2): 163-73[DOI][PubMed]
  • 6. Rifai K, Cornberg J, Mederacke I, Bahr MJ, Wedemeyer H, Malinski P, et al. Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Dig Liver Dis. 2011; 43(6): 491-7[DOI][PubMed]
  • 7. Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008; 135(1): 32-40[DOI][PubMed]
  • 8. Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. J Hepatol. 2013; [DOI][PubMed]
  • 9. Janssens F, de Suray N, Piessevaux H, Horsmans Y, de Timary P, Starkel P. Can transient elastography replace liver histology for determination of advanced fibrosis in alcoholic patients: a real-life study. J Clin Gastroenterol. 2010; 44(8): 575-82[DOI][PubMed]
  • 10. Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci. 2013; 58(1): 265-74[DOI][PubMed]
  • 11. Kitson MT, Kemp WW, Iser DM, Paul E, Wilson JW, Roberts SK. Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease. Liver Int. 2013; 33(5): 698-705[DOI][PubMed]
  • 12. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009; 16(5): 300-14[DOI][PubMed]
  • 13. Hannivoort RA, Hernandez-Gea V, Friedman SL. Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair. 2012; 5(1): 1[DOI][PubMed]
  • 14. Schoniger-Hekele M, Muller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci. 2006; 51(2): 338-45[DOI][PubMed]
  • 15. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011; 11: 91[DOI][PubMed]
  • 16. Omran MM, Farid K, Emran TM, Attallah AA. Fibro-alpha score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol. 2011; 12(2): 74-9[DOI][PubMed]
  • 17. El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, Elakel WA, et al. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int. 2013; [DOI][PubMed]
  • 18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6): 696-9[PubMed]
  • 19. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349(9055): 825-32[PubMed]
  • 20. Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, et al. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011; 8: 53[DOI][PubMed]
  • 21. Azer SA, Murray M, Farrell GC, Stacey NH. Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats. Hepatology. 1993; 18(5): 1224-31[PubMed]
  • 22. Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology. 2006; 44(4): 925-35[DOI][PubMed]
  • 23. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36(4 Pt 1): 986-92[DOI][PubMed]
  • 24. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci. 1994; 39(11): 2426-32[PubMed]
  • 25. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2): 518-26[DOI][PubMed]
  • 26. Rockey DC. Serologic markers of hepatic fibrosis. Gastroenterol Hepatol (N Y). 2008; 4(8): 539-41[PubMed]
  • 27. Cales P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008; 32(6 Suppl 1): 40-51[DOI][PubMed]
  • 28. Poordad FF. FIBROSpect II: a potential noninvasive test to assess hepatic fibrosis. Expert Rev Mol Diagn. 2004; 4(5): 593-7[DOI][PubMed]
  • 29. Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011; 18(1): 23-31[DOI][PubMed]
  • 30. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004; 127(6): 1704-13[PubMed]
  • 31. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005; 51(10): 1867-73[DOI][PubMed]
  • 32. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011; 5(2): 625-34[DOI][PubMed]
  • 33. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010; 53(6): 1013-21[DOI][PubMed]
  • 34. Abraldes JG, Araujo IK, Turon F, Berzigotti A. Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. Gastroenterol Hepatol. 2012; 35(7): 488-95[DOI][PubMed]
  • 35. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991; 37(8): 1379-83[PubMed]
  • 36. Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers. 2000; 15(3): 226-30[PubMed]
  • 37. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000; 26(5): 474-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments